$3500 | Single User
$7000 | Site License
$10500 | Enterprise License

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H1 2017 [Report Updated: 20-06-2017]

Published by Global Markets Direct: 20 Jun 2017 | 87119 | In Stock

Introduction

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H1 2017

Summary

According to the recently published report 'E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H1 2017'; E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) pipeline Target constitutes close to 27 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes.

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - E3 ubiquitin-protein ligase Mdm2 is a protein encoded by the MDM2 gene. It acts as an ubiquitin ligase E3 toward itself and ARRB1. It permits the nuclear export of p53/TP53. It promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. It inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation.

The report 'E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H1 2017' outlays comprehensive information on the E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 7 and 4 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 4 molecules, respectively. Report covers products from therapy areas Oncology and Ophthalmology which include indications Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Lymphoma, Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Glioblastoma Multiforme (GBM), Osteosarcoma, Refractory Multiple Myeloma, Bone Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Dry (Atrophic) Macular Degeneration, Follicular Lymphoma, Hematological Tumor, Leukemias, Liposarcoma, Melanoma, Metastatic Breast Cancer, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Peripheral T-Cell Lymphomas (PTCL), Proliferative Vitreoretinopathy (PVR), Relapsed Multiple Myeloma, Retinoblastoma, Soft Tissue Sarcoma, Uveal Melanoma and Well Differentiated Liposarcoma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.)

- The report reviews E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics and enlists all their major and minor projects

- The report assesses E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H1 2017 [Report Updated: 20-06-2017]

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Overview

    E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Therapeutics Development

    Products under Development by Stage of Development

    Products under Development by Therapy Area

    Products under Development by Indication

    Products under Development by Companies

    Products under Development by Universities/Institutes

    E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Therapeutics Assessment

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Companies Involved in Therapeutics Development

    Aileron Therapeutics Inc

    Amgen Inc

    Daiichi Sankyo Company Ltd

    F. Hoffmann-La Roche Ltd

    Merck & Co Inc

    Novartis AG

    E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Drug Profiles

    ALRN-6924 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    AM-7209 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    AMG-232 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    APG-115 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    ATSP-7041 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    CGM-097 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    CTX-1 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    DS-3032 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    DS-5272 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    HDM-201 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    idasanutlin - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    ISA-27 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    MI-888 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    MMRi-64 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    nutlin-3 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    RO-8994 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Inhibit E3 Ubiquitin-Protein Ligase Mdm2 for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Inhibit MDM2 for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Inhibit MDM2 for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Inhibit MDM2 for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit Hdm2 for Proliferative Vitreoretinopathy - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit MDM2 and MDM4 for Acute Lymphoblastic Leukemia - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit Mdm2 and MdmX for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit MDM2 for Breast Cancer - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit p53-hdm2 for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit p53-MDM2 Interaction for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Vaccine to Target CD105, Yb-1, SOX2, CDH3 and MDM2 for Breast Cancer - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Dormant Products

    E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Discontinued Products

    E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Product Development Milestones

    Featured News & Press Releases

    Jun 03, 2017: Anti-tumor Activity Observed in Phase 1 Trial of Novel P53-Targeting Drug ALRN-6924

    May 18, 2017: Aileron Therapeutics Announces Oral Presentation at ASCO on ALRN-6924 Targeting p53

    Dec 05, 2016: Daiichi Sankyo Presents Phase 1 Data for MDM2 Inhibitor DS-3032 in Acute Myeloid Leukemia and Myelodysplastic Syndrome at the 58th Annual Meeting of the American Society of Hematology

    Nov 30, 2016: Daiichi Sankyo Highlights Clinical Data on DS-3032 at the 58th Annual Meeting of the American Society of Hematology

    Feb 12, 2015: Aileron Therapeutics Initiates Phase 1 Cancer Study of ALRN-6924 in Advanced Hematologic and Solid Malignancies with Wild Type p53

    Dec 05, 2014: Roche to present clinical data on RG-7388 at ASH

    Aug 15, 2013: Aileron Therapeutics Publishes Data Demonstrating ATSP-7041 as First-in-class p53 Pathway Re-activator for the Treatment of Solid and Hematologic Cancers

    Nov 07, 2012: Aileron Therapeutics Presents New Data On Stapled Peptide Oncology Program At EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics

    Oct 31, 2012: Aileron Therapeutics To Present Data On Stapled Peptides At Upcoming Scientific Conferences And Industry Events

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

87119 | GMDHC0858TDB

Number of Pages

72

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Pipeline Review, H1 2018
E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or...
20 Feb 2018 by Global Markets Direct USD $3,500 More Info
Ubiquitin conjugating enzyme Inhibitor -Pipeline Insight, 2018
“Ubiquitin conjugating enzyme Inhibitor - Pipeline Insight, 2018” report by DelveInsight offers comp...
14 Feb 2018 by Delve Insight USD $1,000 More Info
Ubiquitin Specific Proteases (USP) Inhibitor -Pipeline Insight, 2018
“Ubiquitin Specific Proteases (USP) Inhibitor - Pipeline Insight, 2018” report by DelveInsight offer...
14 Feb 2018 by Delve Insight USD $1,000 More Info
Ubiquitin conjugating enzyme Inhibitor -Pipeline Insights, 2017
DelveInsight’s, “Ubiquitin conjugating enzyme Inhibitor-Mechanism of action Insights, 2017”, report ...
01 Sep 2017 by Delve Insight USD $1,000 More Info
Ubiquitin Specific Proteases (USP) Inhibitor -Pipeline Insights, 2017
DelveInsight’s, “Ubiquitin Specific Proteases (USP) Inhibitor-Mechanism of action Insights, 2017”, r...
01 Sep 2017 by Delve Insight USD $1,000 More Info
E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Pipeline Review, H2 2017
E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or...
29 Aug 2017 by Global Markets Direct USD $3,500 More Info
Ubiquitin Specific Proteases (USP) Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Ubiquitin Specific Proteases (USP) Inhibitors-Pipeline Insights, 2017”, report prov...
30 May 2017 by Delve Insight USD $1,000 More Info
Ubiquitin conjugating enzyme inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Ubiquitin conjugating enzyme inhibitors-Pipeline Insights, 2017”, report provides i...
30 May 2017 by Delve Insight USD $1,000 More Info
E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Pipeline Review, H2 2016
E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or...
09 Nov 2016 by Global Markets Direct USD $3,500 More Info
Ubiquitin Proteasome Market: By Cellular Processes (Antigen Processing, Apoptosis, Biogenesis of Organelles, Others) & By Region (Europe, North America, Asia-Pacific, RoW)-Forecast (2016-2022)
During the process of proteolysis, unnecessary or damaged proteins are degraded by the breakage of p...
17 Mar 2016 by Industry ARC USD $5,250 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H1 2017 [Report Updated: 20-06-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data